• Connect with us
    • Information
      • About Us
      • Contact Us
      • Careers
      • Partnerships
      • Advertise With Us
      • Authors
      • Browse Topics
      • Events
      • Disclaimer
      • Privacy Policy
    • Australia
      North America
      World
    Login
    Investing News NetworkYour trusted source for investing success
    • North America
      Australia
      World
    • My INN
    Videos
    Companies
    Press Releases
    Private Placements
    SUBSCRIBE
    • Reports & Guides
      • Market Outlook Reports
      • Investing Guides
    • Button
    Resource
    • Precious Metals
    • Battery Metals
    • Base Metals
    • Energy
    • Critical Metals
    Tech
    Life Science
    Pharmaceutical Market
    Pharmaceutical News
    Pharmaceutical Stocks
    • Pharmaceutical Market
    • Pharmaceutical News
    • Pharmaceutical Stocks
    pharmaceutical investing

    ContraFect Prices $10 Million Public Offering of Common Stock

    Jocelyn Aspa
    Jul. 27, 2018 09:10AM PST
    Pharmaceutical Investing

    ContraFect (NASDAQ:CFRX) has announced the pricing of its underwritten public offering of five million shares of its common stock at a public offering of US$2 per share. As quoted in the press release: All shares in the offering are to be sold by ContraFect. The gross proceeds from the offering will be $10 million, before …

    ContraFect (NASDAQ:CFRX) has announced the pricing of its underwritten public offering of five million shares of its common stock at a public offering of US$2 per share.

    As quoted in the press release:

    All shares in the offering are to be sold by ContraFect. The gross proceeds from the offering will be $10 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by ContraFect. In addition, ContraFect has granted the underwriters a 30-day option to purchase up to an additional 750,000 shares of its common stock at the public offering price, less underwriting discounts and commissions.

    The offering is expected to close on or about July 31, 2018, subject to customary closing conditions.

    Click here to read the full press release.

    public offeringpharmaceutical investingnasdaq:cfrx
    The Conversation (0)

    Go Deeper

    AI Powered

    Vitae Pharmaceuticals Prices Public Offering of Common Stock

    Dynavax Prices Public Offering of Common Stock

    Latest News

    Outlook Reports

    Resource
    • Precious Metals
      • Gold
      • Silver
    • Battery Metals
      • Lithium
      • Cobalt
      • Graphite
    • Energy
      • Uranium
      • Oil and Gas
    • Base Metals
      • Copper
      • Nickel
      • Zinc
    • Critical Metals
      • Rare Earths
    • Industrial Metals
    • Agriculture
    Tech
      • Artificial Intelligence
      • Cybersecurity
      • Gaming
      • Cleantech
      • Emerging Tech
    Life Science
      • Biotech
      • Cannabis
      • Psychedelics
      • Pharmaceuticals

    Featured Pharmaceutical Investing Stocks

    Invion Limited

    IVX:AU

    Cardiol Therapeutics

    CRDL:CA
    More featured stocks

    Browse Companies

    Resource
    • Precious Metals
    • Battery Metals
    • Energy
    • Base Metals
    • Critical Metals
    Tech
    Life Science
    MARKETS
    COMMODITIES
    CURRENCIES
    ×